➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
Baxter

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

CAMBIA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Cambia patents expire, and when can generic versions of Cambia launch?

Cambia is a drug marketed by Assertio and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-three countries.

The generic ingredient in CAMBIA is diclofenac potassium. There are forty-seven drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the diclofenac potassium profile page.

Drug patent expirations by year for CAMBIA
Drug Prices for CAMBIA

See drug prices for CAMBIA

Drug Sales Revenue Trends for CAMBIA

See drug sales revenues for CAMBIA

Recent Clinical Trials for CAMBIA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Scripps HealthPhase 4
DepomedPhase 4
Mayo ClinicPhase 2/Phase 3

See all CAMBIA clinical trials

Pharmacology for CAMBIA
Paragraph IV (Patent) Challenges for CAMBIA
Tradename Dosage Ingredient NDA Submissiondate
CAMBIA FOR SOLUTION;ORAL diclofenac potassium 022165 2011-01-24

US Patents and Regulatory Information for CAMBIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Assertio CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Boehringer Ingelheim
Medtronic
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.